Researchers from Life Extension reported that supplementation with Peak ATP or GlycoCarn on their own also led to reductions in malondialdehyde (MDA), a marker of oxidative stress. GlycoCarn alone led to statistically significant increases in flow-mediated dilation (FMD) - a measure of blood flow and vascular health.
“The treatments demonstrated improvements in certain study parameters related to blood glucose and cardiovascular health, and the results are worthy of further studies being conducted with larger sample sizes,” they wrote in their presentation abstract, which was published in the FASEB Journal.
Peak ATP (TSI USA) is the disodium salt of Adenosine 5′-Triphosphate. ATP is the energy source for tissues, but it also has also been proposed to have functions beyond energy.
GlycoCarn (Sigma-tau) – full chemical name Glycine Propionyl-L-Carnitine Hydrochloride – has been shown to improve the plasma nitrate/nitrite ratio, antioxidant defenses, and cardiovascular risk factors.
The new study aimed to assess the safety, tolerability and effectiveness of the ingredients when given separately or combined.
The researchers recruited 67 people to participate in the randomized, double-blind, placebo-controlled study. The participants were randomly assigned to one of four groups: Group 1 received the combination of Peak ATP (400 mg per day) and GlycoCarn (2,000 mg per day); group 2 received Peak ATP only (400 mg per day); group 3 received GlycoCarn only (2,000 mg per day); and group 4 received placebo .
After 90 days of intervention, the data for the 53 people who actually completed the study indicated that the combination product (group 1) had statistically significant decreases in body weight, BMI, waist and hip circumference, and waist/height ratio, compared to baseline values.
The Peak ATP only group (group 2) experienced significant decreases in blood glucose levels, waist and hip circumference, and waist/height ratio, compared to baseline values, while MDA levels also decreased.
The GlycoCarn only group (group 3) experienced statistically significant increases in FMD and statistically significant decreases in MDA and triglyceride levels, said the researhcers.
The interventions were well-tolerated, they added.
“There were no statistically significant changes in the general health and sexual health questionnaires in either male or female subjects, when compared with baseline or placebo, for any of the active cohorts,” they reported.
Source: FASEB Journal
“A Randomized, Double-blind, Placebo-controlled Study Comparing the Healthy Levels of Blood Sugar and Endothelial Function of PEAK ATP with GlycoCarn, PEAK ATP and GlycoCarn supplementation versus Placebo”
Authors: S. Hirsh, et al.